Long-Acting Formulation: Its extended duration of action allows for less frequent dosing, enhancing patient adherence
The primary resolution source for this market will be information released by Bryan Johnson, however a consensus of credible reporting may also be used
In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
It is used in two very different ways: as a cosmetic ingredient (labeled Copper Tripeptide-1) applied to intact skin at low concentrations, and as a research compound that some individuals reconstitute and use in ways that have never been validated in controlled human trials
Ideal for anti-aging, body composition, sleep, and recovery